Open-label Clinical Trial of Niraparib Combined With Pembrolizumab for Treatment of Advanced or Metastatic Triple-Negative Breast Cancer

IMPORTANCE: Poly(adenosine diphosphate–ribose) polymerase inhibitor and anti–programmed death receptor-1 inhibitor monotherapy have shown limited clinical activity in patients with advanced triple-negative breast cancer (TNBC). OBJECTIVE: To evaluate the clinical activity (primary) and safety (secon...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:JAMA Oncol
Main Authors: Vinayak, Shaveta, Tolaney, Sara M., Schwartzberg, Lee, Mita, Monica, McCann, Georgia, Tan, Antoinette R., Wahner-Hendrickson, Andrea E., Forero, Andres, Anders, Carey, Wulf, Gerburg M., Dillon, Patrick, Lynce, Filipa, Zarwan, Corrine, Erban, John K., Zhou, Yinghui, Buerstatte, Nathan, Graham, Julie R., Arora, Sujata, Dezube, Bruce J., Telli, Melinda L.
Formato: Artigo
Idioma:Inglês
Publicado: American Medical Association 2019
Assuntos:
Original Investigation
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC6567845/
https://ncbi.nlm.nih.gov/pubmed/31194225
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaoncol.2019.1029
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares